FDA Class II Recall: Glenmark's Atomoxetine Capsules Impacted by N-Nitroso Impurity Above Limit
Glenmark Pharmaceuticals Inc., USA, has initiated a Class II recall for 58,368 bottles of Atomoxetine Capsules, USP, 100 mg, due to N-Nitroso Atomoxetine Impurity exceeding FDA limits. This event, stemming from CGMP deviations at Glenmark's Goa, India, manufacturing facility, poses significant supply chain risks for Northstar Rx LLC and procurement teams, necessitating urgent evaluation of alternative suppliers for this ADHD medication.
FDA Initiates Class II Recall for Glenmark's Atomoxetine Due to Nitrosamine Impurity
Glenmark Pharmaceuticals Inc., USA, has initiated a voluntary Class II recall, designated D-0244-2025, impacting 58,368 bottles of Atomoxetine Capsules, USP, 100 mg. This critical action, reported on February 26, 2025, and initiated on January 29, 2025, is a direct consequence of Current Good Manufacturing Practice (CGMP) deviations, specifically the detection of N-Nitroso Atomoxetine Impurity at levels exceeding the FDA's recommended limits. For procurement directors and regulatory affairs heads, this signifies an immediate supply disruption for a key medication used in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The affected product, marketed for Northstar Rx LLC, Memphis, TN 38141, and manufactured by Glenmark Pharmaceuticals Ltd. in Goa, India, carries NDC 16714-761-01. The recall encompasses multiple lot numbers, including 19233270, 19233278, 19233285 (Exp.: 7/2025); 19233806 (Exp.: 8/2025); 19240954 (Exp.: 2/2026); and 19241854 (Exp.: 4/2026). The nationwide distribution pattern within the U.S. means that a broad segment of the market, including pharmacies, distributors, and ultimately patients, will be directly affected. Business development executives must recognize the potential for market share shifts and the urgent need for robust contingency planning to mitigate the impact of such quality failures on product availability and patient care.
Glenmark's Goa Facility Under Scrutiny for Atomoxetine Manufacturing Quality
The manufacturing site, Glenmark Pharmaceuticals Ltd. in Goa, India, is the origin point for the Atomoxetine Capsules subject to this recall. While specific facility details such as FEI numbers or capacity are not disclosed in the immediate recall notice, the CGMP deviations identified point to systemic quality control issues at this location. For supply chain VPs, this highlights the inherent risks associated with offshore manufacturing and the critical importance of rigorous supplier audits and ongoing quality oversight, particularly for active pharmaceutical ingredients (APIs) and finished dosage forms destined for the U.S. market. Any manufacturing site that receives a recall due to CGMP deviations, especially those involving impurities like N-Nitroso Atomoxetine, faces intensified scrutiny from the FDA. This can lead to further inspections, potential import alerts, and significant delays in product approvals or shipments. Procurement teams relying on this facility for other products should initiate a comprehensive review of their quality agreements and audit schedules. The presence of nitrosamine impurities, a known genotoxic concern, indicates a failure in process control or raw material qualification that could extend beyond a single product line, impacting the broader portfolio manufactured at the Goa site.
U.S. Supply Chain Disruption: Atomoxetine Market Impact from Glenmark Recall
The recall of 58,368 bottles of Atomoxetine Capsules, USP, 100 mg, distributed nationwide within the U.S., creates an immediate and tangible disruption in the supply chain for this critical ADHD medication. Northstar Rx LLC, as the entity for whom the product was manufactured, bears the primary commercial impact, facing potential revenue loss, reputational damage, and the logistical challenges of managing a Class II recall. For procurement directors and supply chain VPs across the U.S., this event necessitates an urgent assessment of inventory levels, current contracts with Glenmark Pharmaceuticals Inc., USA, and the potential for stock-outs at the pharmacy level. The market for generic Atomoxetine is competitive, but a recall of this magnitude can quickly strain available supply, leading to price volatility and extended lead times for alternative sources. Business development executives should monitor market dynamics closely for opportunities to capture market share if competitors struggle to meet demand. Furthermore, the incident underscores the vulnerability of relying on single-source manufacturers, particularly for high-volume generic drugs. Companies must evaluate their multi-sourcing strategies and ensure that their supply chain resilience plans are robust enough to absorb such unforeseen regulatory actions and quality failures.
Navigating Atomoxetine Supply Gaps: Identifying and Qualifying Alternative Sources
Given the immediate supply disruption caused by Glenmark's Atomoxetine recall, procurement teams must prioritize the identification and qualification of alternative suppliers. The ChemLifeIntel Knowledge Graph does not currently list specific alternative suppliers for Atomoxetine, underscoring the challenge of rapidly securing new sources for a product impacted by quality issues. This absence of readily available alternatives means that companies must undertake a proactive and expedited due diligence process to identify manufacturers with robust quality systems and a proven track record of compliance, particularly concerning nitrosamine risk mitigation. Qualifying a new supplier for a generic drug like Atomoxetine involves a multi-faceted approach, including comprehensive facility audits, review of regulatory filings (e.g., ANDA submissions), assessment of impurity profiles, and stability data. Regulatory affairs heads understand that this process can be lengthy, often taking months to complete, which exacerbates the immediate supply gap. Companies should leverage industry intelligence platforms to identify potential manufacturers globally, focusing on those with established FDA approvals for similar products. Prioritizing suppliers with a strong history of CGMP compliance and a transparent approach to impurity control will be paramount to minimize future regulatory risks and ensure continuity of supply.
Broader Regulatory Landscape: Nitrosamine Contamination and Industry Compliance
This recall of Atomoxetine due to N-Nitroso Atomoxetine Impurity is not an isolated incident but rather reflects a persistent and industry-wide challenge with nitrosamine contamination. The FDA and other global regulatory bodies have intensified scrutiny on pharmaceutical manufacturers to identify, assess, and mitigate the risk of these genotoxic impurities in drug products. This ongoing regulatory pressure means that all pharmaceutical companies, regardless of their product portfolio, must have robust impurity control strategies embedded within their quality management systems. The recent parallel events, such as the FDA Class II Recall for Essential Wellness Pharma's Progesterone Injection due to sterility issues, and the FDA hearing concerning Amgen's Tavneos, highlight a broader environment of heightened regulatory oversight across the life sciences sector. For regulatory affairs heads and business development executives, this signals a non-negotiable imperative for proactive risk assessment and continuous monitoring of raw materials, manufacturing processes, and finished product testing. Companies that fail to adequately address nitrosamine risks face not only recalls but also potential Warning Letters, import alerts, and significant reputational damage. Investing in advanced analytical capabilities and collaborating with API suppliers to ensure their processes are optimized for nitrosamine control are critical steps to maintain compliance and safeguard market access in a landscape where impurity control is a top regulatory priority.
Remediation Pathways and Future Regulatory Posture for Glenmark Pharmaceuticals
Following a Class II recall for CGMP deviations and impurity issues, Glenmark Pharmaceuticals Inc., USA, and its manufacturing arm, Glenmark Pharmaceuticals Ltd. in Goa, India, are now on a critical remediation pathway. The firm is expected to conduct a thorough root cause analysis to identify precisely how the N-Nitroso Atomoxetine Impurity formed or was introduced and why it exceeded FDA limits. This will necessitate a comprehensive review of their manufacturing processes, raw material sourcing, and quality control procedures for Atomoxetine. For regulatory affairs teams, the adequacy and timeliness of Glenmark’s corrective and preventive actions (CAPA) will be under intense FDA scrutiny. Failure to implement effective CAPA could lead to further regulatory actions, including potential FDA Warning Letters, increased inspection frequency, or even import alerts for products manufactured at the Goa facility. Supply chain VPs should anticipate potential long-term impacts on product availability from this site, even for unaffected products, as the company dedicates resources to address the identified deficiencies. Business development executives must factor in the potential for market share erosion if Glenmark struggles to restore confidence and consistent supply. Proactive communication with the FDA and a transparent, robust remediation plan will be crucial for Glenmark to mitigate the commercial and regulatory fallout from this significant recall event.